LFMD · CIK 0000948320

What LifeMD, Inc. told the SEC could break it.

LifeMD's disclosures cluster on the regulatory underpinnings of its telehealth model and a structural dependence. Most of its consultations are asynchronous and depend on states permitting asynchronous telehealth, and it relies on an affiliated professional corporation it does not own, LifeMD PC, and its providers to deliver the clinical care that drives revenue — so restrictions on either would disrupt the core model. A pointed regulatory hit already landed: in early 2025 the FDA declared the GLP-1 drug shortages resolved, ending the legal basis for mass compounding and forcing LifeMD to restructure its weight-management program, a major revenue driver, away from compounded GLP-1s. It also carries variable-rate debt under its Avenue Facility, against $47.3 million of total liabilities at year-end.

4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.

In its own words

What could break it.

Regulatory & policy

Asynchronous telehealth legality across statesmedium
Most consultations are asynchronous and depend on state jurisdictions permitting asynchronous telehealth; restrictions or enforcement changes could disrupt the core operating model.
“The majority of the consultations provided through our platform are asynchronous consultations for customers located in jurisdictions that permit the use of asynchronous telehealth.”
SEC filing →As of 2026
FDA end of GLP-1 (semaglutide/tirzepatide) mass compoundingmedium
In early 2025 the FDA declared the GLP-1 drug shortages resolved, ending the legal basis for mass compounding and forcing LifeMD to restructure its weight-management program (a major revenue driver) away from compounded GLP-1s.
“In early 2025, the FDA determined shortages for semaglutide (marketed as Ozempic® and Wegovy®) and tirzepatide (marketed as Mounjaro® and Zepbound®) were resolved, effectively ending the legal basis for mass compounding”
SEC filing →As of 2026

Liquidity & debt

Avenue Facility term loans / variable-rate debtmedium
The company carries variable-rate debt under the Avenue Facility (with attached warrants and partial debt-to-equity conversions) and had total liabilities of $47.3 million at year-end 2025, exposing it to interest-rate and refinancing risk.
“As of December 31, 2025, the Company had total liabilities of $47.3 million.”
SEC filing →As of 2026

Other disclosures

Dependence on affiliated professional corporation (LifeMD PC)medium
LifeMD relies on its affiliated professional corporation, LifeMD PC, and its providers to deliver the clinical consultations that drive revenue — a friendly-PC structural dependence the company does not directly own.
“We depend on LifeMD PC and their providers to deliver quality healthcare consultations and services”
SEC filing →As of 2026

The hidden graph

Who it depends on, and who depends on it.

Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.

Its suppliers

Amazon Web Services (Amazon.com, Inc.)
“We currently host our platform, serve our customers, and support our operations in the U.S. using Amazon Web Services (“AWS”), a provider of cloud infrastructure services, as well as through partner pharmacies and other third-party service providers, including shipping providers and contract manufacturers.”
Cited →

In the MyPRIA app, this is checked against the companies you actually own.

← World Watch